Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 18Prostatic Neoplasms 6Carcinoma, Renal Cell 5Uveal Melanoma 4Sarcoma 4Histiocytoma, Malignant Fibrous 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Liposarcoma 2Leukemia 2Gastrointestinal Stromal Tumors 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Carcinoma, Endometrioid 2Bone Neoplasms 2Vaginal Neoplasms 1Urogenital Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Fluorouracil 6Cisplatin 4Radiotherapy, Intensity-Modulated 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Capecitabine 3dehydroftorafur 2Specimen Handling 2Mitomycin 2Cetuximab 2toripalimab 1rocakinogene sifuplasmid 1pembrolizumab 1durvalumab 1atezolizumab 1Vaccines 1VGX-3100 1Taxes 1Radiosurgery 1Radiation 1Platinum 1Paclitaxel 1Nivolumab 1Mitozytrex 1Mitomycins 1MEDI0457 1Ipilimumab 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anal Canal Carcinoma × CTLA-4 Antigen × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡